Cyproterone Acetate (Androcur®)

Common name: Cyproterone Acetate
Brand name: Androcur®
 

What is Cyproterone Acetate?

Cyproterone Acetate is an anti-androgen therapy used to treat advanced prostate cancer. It works by slowing or stopping the production of testosterone in the body to slow the growth of prostate cancer cells.
 

How is Cyproterone Acetate administered?

Cyproterone Acetate is administered either orally as a tablet or as an intramuscular injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cyproterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Hair loss
  • Impotence
  • Increased bowel movements
  • Increased hair growth
  • Loss of energy
  • Reduced sexual interest
  • Weight gain
 

Is Cyproterone Acetate covered in my province or territory?

Cyproterone acetate is covered by all provincial/territorial drug programs.
 
Last Reviewed: July 2017

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive